ISU Abxis이수앱지스
086890 · KOSDAQ · ₩086890 · 이수앱지스
- Market cap
- ₩147B
- Enterprise value
- ₩142B
- P/E
- —
- P/B
- 1.2×
- Dividend yield
- 0.0%
- ROE
- −14.1%
- Net margin
- −32.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−43.4% from the high
₩2,890Today: ₩3,500 – ₩3,610₩6,350
Returns
- 1W−4.5%
- 1M−5.6%
- 3M+20.8%
- 6M−25.9%
- YTD−30.2%
- 1Y−29.5%
- Volume today
- 65,353
- 0.6× the 20-day average
- Traded today
- ₩232M
- Listed shares
- 40,774,990
- EPS (12 months)
- −₩411
- Earnings yield −11.4%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 36 of 100 (50 is a normal day for this stock).
- MomentumFlat2% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
ISU Abxis stock overview
ISU Abxis (이수앱지스, KRX: 086890) is listed on KOSDAQ, in the Biotech & Pharma sector. The company runs a single pharmaceutical business focused on biopharmaceutical products, mainly enzyme replacement therapies Abcertin (for Gaucher disease) and Pavagal (for Fabry disease), plus Clotinab, an antibody therapy used after coronary angioplasty to prevent restenosis-related cardiovascular events. Its shares closed at ₩3,595 on Oct 28, 2026, up 1.70% on the day, giving it a market value of ₩147B.
Key facts
- Market cap
- ₩147B
- Sector
- Biotech & Pharma
- Latest price change
- +1.70%
- As of
- Oct 28, 2026
- Main business
- The company runs a single pharmaceutical business focused on biopharmaceutical products, mainly enzyme replacement therapies Abcertin (for Gaucher disease) and Pavagal (for Fabry disease), plus Clotinab, an antibody therapy used after coronary angioplasty to prevent restenosis-related cardiovascular events.
Quick answers about ISU Abxis
- What does ISU Abxis do?
- The company runs a single pharmaceutical business focused on biopharmaceutical products, mainly enzyme replacement therapies Abcertin (for Gaucher disease) and Pavagal (for Fabry disease), plus Clotinab, an antibody therapy used after coronary angioplasty to prevent restenosis-related cardiovascular events. It also generates product sales from other drugs and technology license revenue. Its products are sold domestically in Korea through designated wholesalers to hospitals, and overseas mainly through partner pharmaceutical companies, with its largest overseas sales concentrated in the MENA region.
- What is the market cap of ISU Abxis?
- The market capitalisation of ISU Abxis was ₩147B at the close on Oct 28, 2026.
- Who are the largest shareholders of ISU Abxis?
- According to the latest official filings, the largest reported holders are Lee Su Chemical (35.93%, as of Jul 23, 2026); Kim Se-min (1.74%, as of Jul 22, 2026); Kim Sang-beom (0.45%, as of Jul 22, 2026).
- When is the next earnings report from ISU Abxis?
- Korean companies rarely announce results dates in advance. Based on when ISU Abxis filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own ISU Abxis?
- Yes. The National Pension Service held 0.20% of ISU Abxis shares as of Dec 31, 2020.
Company profile
The company runs a single pharmaceutical business focused on biopharmaceutical products, mainly enzyme replacement therapies Abcertin (for Gaucher disease) and Pavagal (for Fabry disease), plus Clotinab, an antibody therapy used after coronary angioplasty to prevent restenosis-related cardiovascular events. It also generates product sales from other drugs and technology license revenue. Its products are sold domestically in Korea through designated wholesalers to hospitals, and overseas mainly through partner pharmaceutical companies, with its largest overseas sales concentrated in the MENA region.
Written by AI from the company's latest annual report.
- Korean name
- 이수앱지스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 유준수
- Founded
- Mar 2001
- Listed
- Feb 2009
- Listed shares
- 40,774,990
- Fiscal year ends
- Month 12
- Website
- www.abxis.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturitySep 22, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Investor relations (IR) eventAug 10, 2026
- Preliminary earningsAug 6, 2026
- Amended: 5%+ holding reportJul 23, 2026
Titles in Korean until English translations are added.
Also known as: ISU Abxis / 이수앱지스 / 086890 / KRX:086890
Source: KRX statistical information